Hi. Hello, and welcome to ProKidney's annual meeting. I am Pablo Legorreta, Chairman of the Board, and I will act as chairman for this meeting. We're conducting a hybrid meeting with both in-person and virtual components in order to maximize the participation of our stockholders regardless of their location in the world. We have provided the agenda and the rules of conduct for the meeting on our meeting website. The notice of annual meeting of stockholders, notice of internet availability of proxy materials, proxy statement, proxy, and affidavit of meeting will be made a part of the minutes of this meeting. This meeting will be limited to the formal business of the stockholders. I would like to begin the meeting by introducing the members of the company's board of directors.
In addition to myself, our board includes Dr. Bruce Culleton, our Chief Executive Officer, William Doyle, our Lead Independent Director and Chair of the Nominating and Corporate Governance Committee, Jennifer Fox, Chair of the Audit Committee, José Ignacio Jiménez Santos, Dr. Alan Lotvin, Chair of the Talent and Compensation Committee, Dr. Brian Pereira, Chair of the Research & Development Committee, and Dr. Uma Sinha. Also present today are members of the management team, including James Coulston, Chief Financial Officer, and Todd Girolamo, Chief Legal Officer and Corporate Secretary. In addition, a representative of Ernst & Young, our independent auditor, is also present today. During the Q&A period at the end of the meeting, Ernst & Young, together with me, Dr. Culleton, and Mr. Coulston, will be available to answer questions that comport with the rules of conduct and that are relevant to the meeting.
In order to conduct an orderly meeting, we ask that participants follow the rules of conduct that, as I mentioned, have been posted on the meeting website. I will now ask Todd Girolamo, who is acting as Secretary of the meeting, to report on the quorum.
Thanks, Pablo. The stockholder list shows that holders of 301,966,357 shares of common stock are entitled to vote at this meeting. The Inspector of Election has informed us that a majority of all shares entitled to vote at this meeting are represented in person or by proxy. I hereby declare that a quorum is present and that the meeting is duly convened.
Thank you, Todd. In accordance with the notice of the meeting, the 2026 annual meeting of stockholders of ProKidney Corporation is called to order. There are two proposals to be considered at today's meeting, and the meeting will take place as described in the agenda. A vote will be taken on each of the resolutions, and in accordance with applicable law and our bylaws, Mr. John R. Merva, a representative of American Election Services, LLC, has been appointed and duly sworn to act as the Inspector of Election. Mr. Merva will tabulate the votes cast and certify the votes taken at this meeting. Voting will open upon reading each proposed resolution, and the voting process will remain open until later in the meeting when I declare the voting closed.
If you have any questions, please raise your hand if you're attending in person or select the Ask a Question option online on the meeting website to submit your questions at any time during the meeting. At the conclusion of the meeting, we will attempt to answer questions as time allows. The first item of business is the election of three director nominees of the company. The nominees are listed in the proxy statement made available to you. Directors elected today will hold office until the 2029 annual meeting and until their successors are elected. The candidates for directors who have been nominated to serve as directors by the company's Nominating and Corporate Governance Committee and Board of Directors are William F. Doyle, Alan M. Lotvin, MD, and Brian Pereira, MD. A separate resolution for the election of each of the nominees is proposed.
No other nominations for directors were received. I declare the nominations closed. We will now move to the next proposal. The second item of business is to ratify on a non-binding advisory basis the appointment by the board of directors of E&Y as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. No further business is on the agenda to become before this meeting, I now declare the polls open for each matter to be voted on. The Inspector of Election has the stockholder list of the company as of the record date set for purpose of determining stockholders eligible to vote at the meeting. This list is available if any stockholder wishes to examine it. If you have provided your proxy card, your shares will be voted accordingly.
If you're currently holding a proxy card and attending the meeting in person, please turn it to Mr. Girolamo. Please do not fill out a ballot unless you want to change your proxy vote. If you desire a ballot and are attending the meeting in person, please raise your hand and one will be brought to you. If you have not submitted your votes or would like to change your votes, you may also do this online at this time. If you have not already done so and are attending the meeting live in Boston, please provide your proxy or ballot to Mr. Girolamo, who will communicate the votes to our Inspector of Election. I declare the polls now closed and ask that the Inspector of Election collect and tabulate the ballots.
The Inspector of Election has informed us that the preliminary vote report shows that the requisite number of shares have been voted for each of the nominees for election to the board of directors and for the ratification of the appointment of Ernst & Young as our independent registered public accounting firm for the fiscal year ending December 31, 2026. Because the affirmative vote of the holders of the requisite number of shares has been obtained on each proposal, we hereby declare that each proposal has been officially approved and ratified by the stockholders. We will report the final vote results in a Form 8-K to be filed with the SEC.
Thank you, Todd. I will now open the floor to questions. Please remember to follow the rules of conduct. If you would like to be recognized, please raise your hand or select the Ask Question option online on the meeting website. We're obliged to say that management remarks and responses to any questions may contain forward-looking statements. Actual results may differ significantly from results discussed in the forward-looking statements. Factors that might cause such a difference include those set forth in the company's SEC filings, including the company's annual report on Form 10-K for the fiscal year ended December 31st, 2025. As there have been no questions raised, the business of the meeting is concluded. Before we adjourn, however, Mr. Culleton will make some concluding remarks.
Thank you, Pablo. 2025 was a pivotal year for ProKidney. Since our last general meeting, we aligned with the FDA on an accelerated approval pathway for rilparencel using eGFR slope as a surrogate endpoint. We presented positive Phase II data from the REGEN-007 clinical study as a late-breaking clinical trial at the American Society of Nephrology Kidney Week. The full manuscript from this work was published, along with an invited editorial in the May edition of the Clinical Journal of the American Society of Nephrology. We also generated significant enrollment momentum in the Phase III PROACT 1 study, and we initiated expansion of ProKidney's in-house manufacturing footprint in Winston-Salem, North Carolina.
As we look to the balance of 2026, we remain on track to complete enrollment in our Phase III study this year, and we anticipate readout of the eGFR slope surrogate endpoint in Q2 2027 as we seek accelerated approval of rilparencel. As a company, we remain grounded by the challenges that lie ahead as our team steadily advances toward its goal of delivering a novel cellular therapeutic, rilparencel, to patients with advanced chronic kidney disease and Type 2 diabetes. In closing, to our employees, thank you for your steadfast commitment to our mission. To our investigators and clinical study participants, your partnership is essential to our progress. Thank you. To our shareholders, thank you for your continued trust and commitment as we work to transform the therapeutic landscape for patients with advanced chronic kidney disease and Type 2 diabetes.
Well, thanks, Bruce, and thanks to all for attending today's meeting and for the interest you have shown in ProKidney. Since there are no other matters to come before the meeting, the meeting is hereby adjourned.
This concludes today's meeting. You may now disconnect.